Bushra Salman
Overview
Explore the profile of Bushra Salman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elshafie O, Khalil A, Salman B, Atabani A, Al-Sayegh H
Endocrinol Diabetes Metab
. 2024 Jun;
7(4):e00505.
PMID: 38932429
Objectives: To determine the incidence, presentation, frequency and management of immune checkpoint inhibitors (ICI)-related endocrinopathies in a comprehensive cancer centre in Oman, particularly with programme death 1/programme death-ligand 1 (PD-1/PD-L1)...
2.
Mohamed A, Salman B, Shaikh A
J Oncol Pharm Pract
. 2024 May;
:10781552241252100.
PMID: 38710475
Introduction: The study evaluates the first-line application of pembrolizumab in metastatic non-small-cell lung cancer (mNSCLC), head and neck squamous cell cancer (HNSCC), gastric cancer, and renal cell carcinoma. Utilizing the...
3.
Salman B, AlWard N, Al-Hashami Z, Al-Sharqi H, Al-Sayegh H, Burney I
Cureus
. 2023 Nov;
15(10):e47050.
PMID: 38021572
Introduction Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple cancers over the last decade. They work by employing the immune system and exhibiting activity over T cells resulting...
4.
Salman B, Al-Rasbi F, Al-Ward N, Al-Baimani K, Burney I, Abdullah E, et al.
Sultan Qaboos Univ Med J
. 2023 Jun;
23(2):233-238.
PMID: 37377836
Objectives: This study aimed to estimate the prevalence and evaluate risk factors of hypersensitivity reactions (HSRs) to platinum-based compounds (PBCs) in cancer patients. PBCs play an important role in cancer...
5.
Salman B, Al-Hashar A, Al-Khirbash A, Al-Zakwani I
Int J Infect Dis
. 2021 Jul;
109:137-141.
PMID: 34242762
Objective: To evaluate the clinical and financial impact of clinical pharmacists' interventions (CPIs) on antimicrobial use at a 500-bed multidisciplinary tertiary care hospital in Oman. Methods: A retrospective analysis of...
6.
Al-Riyami N, Salman B, Al-Rashdi A, Al-Dughaishi T, Al-Haddabi R, Hassan B
Sultan Qaboos Univ Med J
. 2021 Jul;
21(2):e244-e252.
PMID: 34221472
Objectives: This study was conducted to assess pregnancy outcomes in women with systemic lupus erythematosus (SLE) in Oman. Methods: A retrospective cohort study of 149 pregnancies in 98 women with...
7.
Salman B, Al-Khabori M
J Oncol Pharm Pract
. 2020 Dec;
27(3):693-701.
PMID: 33302823
Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic outcomes with these agents, many...
8.
Salman B, Al-Khabori M, Al-Huneini M, Al-Rawas A, Dennison D, Al-Zaabi M
Int J Hematol
. 2020 May;
112(2):210-216.
PMID: 32468179
Hepatic veno-occlusive disease (VOD) is a life-threatening complication following hematopoietic stem cell transplant (HSCT). Busulfan has a narrow therapeutic index and its concentration was found to correlate with VOD. Our...
9.
Al Riyami N, Al Riyami M, Al Hajri A, Al Saidi S, Salman B, Al Kalbani M
Oman Med J
. 2019 May;
34(3):200-204.
PMID: 31110626
Objectives: We sought to assess the prevalence of gestational trophoblastic diseases (GTD) among pregnant women at Sultan Qaboos University Hospital (SQUH) and compare our results with the international studies. We...
10.
Salman B, Al-Zaabi M, Al-Huneini M, Dennison D, Al-Rawas A, Al-Kindi S, et al.
Hematol Oncol Stem Cell Ther
. 2017 Apr;
10(2):70-78.
PMID: 28408108
Busulfan (Bu)-based preparative regimens in hematopoietic stem cell transplantation are commonly used. Previous studies have shown that Bu at a fixed dose of 3.2mg/kg/day (FBD) given intravenously decreases variability in...